New antiarrhythmic targets to control intracellular calcium handling

Netherlands Heart Journal

Volumn 22, Issue 5, 2014, Pages 198-213

  Driessen, H E ^a   Bourgonje, V J A ^a   van Veen, T A B ^a   Vos, M A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Arrhythmia; Calcium; Drugs; Treatment

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY) PHENYL] ETHYL] ISOTHIOUREA METHANESULFONATE; 2 [4 (2, 5 DIFLUOROBENZYLOXY) PHENOXY] 5 ETHOXYANILINE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; FK 506 BINDING PROTEIN; ISOPRENALINE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO] METHYL] PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM ION; RANOLAZINE; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; EXCITATION CONTRACTION COUPLING; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION PREVENTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHY; INTRACELLULAR SIGNALING; MEMBRANE POTENTIAL; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SUDDEN CARDIAC DEATH; TORSADE DES POINTES;

EID: 84900472883     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-014-0549-5     Document Type: Review

References (93)

1. Currie S, Elliott EB, Smith GL, et al. Two candidates at the heart of dysfunction: the ryanodine receptor and calcium/calmodulin protein kinase ii as potential targets for therapeutic intervention-an in vivo perspective. Pharmacol Ther. 2011; 131: 204-20.
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001; 345: 1473-82.
3. Sen-Chowdhry S, McKenna WJ. Sudden death from genetic and acquired cardiomyopathies. Circulation. 2012; 125: 1563-76.
4. Kamath GS, Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog Cardiovasc Dis. 2008; 50: 439-48.
5. Antoons G, Oros A, Bito V, et al. Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment. J Electrocardiol. 2007; 40: S8-S14.
6. Jansen JA, van Veen TA, de Bakker JM, et al. Cardiac connexins and impulse propagation. J Mol Cell Cardiol. 2010; 48: 76-82.
7. Rudy Y. Molecular basis of cardiac action potential repolarization. Ann N YAcad Sci. 2008; 1123: 113-8.
8. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002; 415: 198-205.
9. Burashnikov A, Antzelevitch C. Late-phase 3 ead. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol. 2006; 29: 290-5.
10. Diaz ME, Trafford AW, O'Neill SC, et al. Measurement of sarcoplasmic reticulum ca2+ content and sarcolemmal ca2+ fluxes in isolated rat ventricular myocytes during spontaneous ca2+ release. J Physiol. 1997; 501(Pt 1): 3-16.
11. Fink M, Noble PJ, Noble D. Ca(2)(+)-induced delayed after depolarizations are triggered by dyadic subspace ca2(2)(+) affirming that increasing serca reduces after contractions. Am J Physiol Heart Circ Physiol. 2011; 301: H921-35.
12. Guo T, Zhang T, Mestril R, et al. Ca2+/calmodulin-dependent protein kinase ii phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res. 2006; 99: 398-406.
13. Lederer WJ, Tsien RW. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in purkinje fibres. J Physiol. 1976; 263: 73-100.
14. Mechmann S, Pott L. Identification of na-ca exchange current in single cardiac myocytes. Nature. 1986; 319: 597-9.
15. Antoons G, Willems R, Sipido KR. Alternative strategies in arrhythmia therapy: evaluation of na/ca exchange as an anti-arrhythmic target. Pharmacol Ther. 2012; 134: 26-42.
16. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med. 2004; 14: 61-6.
17. Volders PG, VosMA, Szabo B, et al. Progress in the understanding of cardiac early after depolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res. 2000; 46: 376-92.
18. Zhao Z, Wen H, Fefelova N, et al. Revisiting the ionicmechanisms of early after depolarizations in cardiomyocytes: predominant by ca waves or ca currents? Am J Physiol Heart Circ Physiol. 2012; 302: H1636-44.
19. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006; 92 Suppl 4: iv1-5.
20. Zipes DP, Camm AJ, Borggrefe M, et al. Acc/aha/esc 2006 guidelines formanagement of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the american college of cardiology/american heart association task force and the european society of cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the european heart rhythm association and the heart rhythm society. Circulation. 2006; 114: e385-484.
21. Gjesdal K. Non-investigational antiarrhythmic drugs: long-term use and limitations. Expert Opin Drug Saf. 2009; 8: 345-55.
22. Kendall MJ. Clinical trial data on the cardioprotective effects of betablockade. Basic Res Cardiol. 2000; 95 Suppl 1: I25-30.
23. Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (cupid): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum ca2+-atpase in patients with advanced heart failure. Circulation. 2011; 124: 304-13.
24. Sipido KR, Bito V, Antoons G, et al. Na/ca exchange and cardiac ventricular arrhythmias. Ann N YAcad Sci. 2007; 1099: 339-48.
25. Tanaka H, Nishimaru K, Aikawa T, et al. Effect of sea0400, a novel inhibitor of sodium-calciumexchanger, onmyocardial ionic currents. Br J Pharmacol. 2002; 135: 1096-100.
26. Matsuda T, Arakawa N, Takuma K, et al. Sea0400, a novel and selective inhibitor of the na+-ca2+ exchanger, attenuates reperfusion injury in the in vitro and in vivo cerebral ischemic models. J Pharmacol Exp Ther. 2001; 298: 249-56.
27. Bourgonje VJ, Vos MA, Ozdemir S, et al. Combined na(+)/ca(2+) exchanger and l-type calcium channel block as a potential strategy to suppress arrhythmias and maintain ventricular function. Circ Arrhythm Electrophysiol. 2013; 6: 371-9.
28. Ozdemir S, Bito V, Holemans P, et al. Pharmacological inhibition of na/ca exchange results in increased cellular ca2+ load attributable to the predominance of forward mode block. Circ Res. 2008; 102: 1398-405.
29. Birinyi P, Acsai K, Banyasz T, et al. Effects of sea0400 and kb-r7943 on na+/ca2+ exchange current and l-type ca2+ current in canine ventricular cardiomyocytes. Naunyn Schmiedeberg's Arch Pharmacol. 2005; 372: 63-70.
30. Nagy ZA, Virag L, Toth A, et al. Selective inhibition of sodiumcalcium exchanger by sea-0400 decreases early and delayed after depolarization in canine heart. Br J Pharmacol. 2004; 143: 827-31.
31. Farkas AS, Makra P, Csik N, et al. The role of the na+/ca2+ exchanger, i(na) and i(cal) in the genesis of dofetilide-induced torsades de pointes in isolated, av-blocked rabbit hearts. Br J Pharmacol. 2009; 156: 920-32.
32. Milberg P, Pott C, FinkM, et al. Inhibition of the na+/ca2+ exchanger suppresses torsades de pointes in an intact heart model of long qt syndrome-2 and long qt syndrome-3. Heart Rhythm. 2008; 5: 1444-52.
33. Tanaka H, Shimada H, Namekata I, et al. Involvement of the na+/ca2+ exchanger in ouabain-induced inotropy and arrhythmogenesis in guinea-pig myocardium as revealed by sea0400. J Pharmacol Sci. 2007; 103: 241-6.
34. Nagasawa Y, Zhu BM, Chen J, et al. Effects of sea0400, a na+/ca2+ exchange inhibitor, on ventricular arrhythmias in the in vivo dogs. Eur J Pharmacol. 2005; 506: 249-55.
35. Amran MS, Hashimoto K, Homma N. Effects of sodium-calcium exchange inhibitors, kb-r7943 and sea0400, on aconitine-induced arrhythmias in guinea pigs in vivo, in vitro, and in computer simulation studies. J Pharmacol Exp Ther. 2004; 310: 83-9.
36. Bourgonje VJ, Schoenmakers M, Beekman JD, et al. Relevance of calmodulin/camkii activation for arrhythmogenesis in the av block dog. Heart Rhythm. 2012; 9: 1875-83.
37. Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010; 59: 1-30.
38. Dulhunty AF, Casarotto MG, Beard NA. The ryanodine receptor: a pivotal ca2+ regulatory protein and potential therapeutic drug target. Curr Drug Targets. 2011; 12: 709-23.
39. Ather S, Respress JL, Li N, et al. Alterations in ryanodine receptors and related proteins in heart failure. Biochim Biophys Acta. 1832; 2013: 2425-31.
40. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009; 15: 380-3.
41. Watanabe H, Steele DS, Knollmann BC. Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2011; 109: 712-3.
42. Wehrens XH, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004; 304: 292-6.
43. Loughrey CM, Otani N, Seidler T, et al. K201 modulates excitationcontraction coupling and spontaneous ca2+ release in normal adult rabbit ventricular cardiomyocytes. Cardiovasc Res. 2007; 76: 236-46.
44. Kimura J, Kawahara M, Sakai E, et al. Effects of a novel cardioprotective drug, jtv-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol. 1999; 79: 275-81.
45. Kiriyama K, Kiyosue T, Wang JC, et al. Effects of jtv-519, a novel anti-ischaemic drug, on the delayed rectifier k+ current in guinea-pig ventricular myocytes. Naunyn Schmiedeberg's Arch Pharmacol. 2000; 361: 646-53.
46. Nakaya H, Furusawa Y, Ogura T, et al. Inhibitory effects of jtv-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts. Br J Pharmacol. 2000; 131: 1363-72.
47. Otani N, Matsuda R, Oda K, et al. Protective effect of k201 on isoproterenol-induced and ischemic-reperfusion-induced ventricular arrhythmias in the rat: comparison with diltiazem. J Cardiovasc Pharmacol Ther. 2013; 18: 184-90.
48. Stams TR, Oros A, der Nagel R, et al. Effects of k201 on repolarization and arrhythmogenesis in anesthetized chronic atrioventricular block dogs susceptible to dofetilide-induced torsade de pointes. Eur J Pharmacol. 2011; 672: 126-34.
49. Sedej S, Heinzel FR, Walther S, et al. Na+-dependent sr ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human cpvt mutation. Cardiovasc Res. 2010; 87: 50-9.
50. Chen YJ, Chen YC, Wongcharoen W, et al. Effect of k201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes. Br J Pharmacol. 2008; 153: 915-25.
51. Hasumi H, Matsuda R, Shimamoto K, et al. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization. Eur J Pharmacol. 2007; 555: 54-60.
52. Liu N, Colombi B, Memmi M, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a ryr2 r4496c knock-in mouse model. Circ Res. 2006; 99: 292-8.
53. Kumagai K, Nakashima H, Gondo N, et al. Antiarrhythmic effects of jtv-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol. 2003; 14: 880-4.
54. Zhou Q, Xiao J, Jiang D, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced ca2+ release. Nat Med. 2011; 17: 1003-9.
55. Lou LL, Lloyd SJ, Schulman H. Activation of the multifunctional ca2+/calmodulin-dependent protein kinase by autophosphorylation: Atpmodulates production of an autonomous enzyme. ProcNatlAcad Sci U S A. 1986; 83: 9497-501.
56. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther. 2005; 106: 39-55.
57. Guo J, Duff HJ. Calmodulin kinase ii accelerates l-type ca2+ current recovery from inactivation and compensates for the direct inhibitory effect of [ca2+]i in rat ventricular myocytes. J Physiol. 2006; 574: 509-18.
58. Zhang T, Johnson EN, GuY, et al. The cardiac-specific nuclear delta(b) isoform of ca2+/calmodulin-dependent protein kinase ii induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2a activity. J Biol Chem. 2002; 277: 1261-7.
59. Anderson ME. Camkii and a failing strategy for growth in heart. J Clin Invest. 2009; 119: 1082-5.
60. Zhang T, Brown JH. Role of ca2+/calmodulin-dependent protein kinase ii in cardiac hypertrophy and heart failure. Cardiovasc Res. 2004; 63: 476-86.
61. SumiM, Kiuchi K, Ishikawa T, et al. The newly synthesized selective ca2+/calmodulin dependent protein kinase ii inhibitor kn-93 reduces dopamine contents in pc12h cells. Biochem Biophys Res Commun. 1991; 181: 968-75.
62. Anderson ME, Braun AP, Wu Y, et al. Kn-93, an inhibitor of multifunctional ca++/calmodulin-dependent protein kinase, decreases early after depolarizations in rabbit heart. J Pharmacol Exp Ther. 1998; 287: 996-1006.
63. Rezazadeh S, Claydon TW, Fedida D. Kn-93 (2-[n-(2-hydroxyethyl)]-n-(4-methoxybenzenesulfonyl)]amino-n-(4-chlorocinnamyl)-n-methylbenzylamine), a calcium/calmodulindependent protein kinase ii inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther. 2006; 317: 292-9.
64. Ather S, Wang W, Wang Q, et al. Inhibition of camkii phosphorylation of ryr2 prevents inducible ventricular arrhythmias in mice with duchenne muscular dystrophy. Heart Rhythm. 2013; 10: 592-9.
65. Bapat A, Nguyen TP, Lee JH, et al. Enhanced sensitivity of aged fibrotic hearts to angiotensin ii-and hypokalemia-induced early after depolarization-mediated ventricular arrhythmias. Am J Physiol Heart Circ Physiol. 2012; 302: H2331-40.
66. Said M, Becerra R, Valverde CA, et al. Calcium-calmodulin dependent protein kinase ii (camkii): a main signal responsible for early reperfusion arrhythmias. J Mol Cell Cardiol. 2011; 51: 936-44.
67. Morita N, Lee JH, Bapat A, et al. Glycolytic inhibition causes spontaneous ventricular fibrillation in aged hearts. Am J Physiol Heart Circ Physiol. 2011; 301: H180-91.
68. Liu N, Ruan Y, Denegri M, et al. Calmodulin kinase ii inhibition prevents arrhythmias in ryr2(r4496c+/-) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol. 2011; 50: 214-22.
69. Sag CM, Wadsack DP, Khabbazzadeh S, et al. Calcium/calmodulindependent protein kinase ii contributes to cardiac arrhythmogenesis in heart failure. Circ Heart Fail. 2009; 2: 664-75.
70. Pu J, Zhang CT, Bai R, et al. Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model. Zhonghua Xin Xue Guan Bing Za Zhi. 2005; 33: 364-8.
71. Kirchhof P, Fabritz L, Kilic A, et al. Ventricular arrhythmias, increased cardiac calmodulin kinase ii expression, and altered repolarization kinetics in anp receptor deficient mice. J Mol Cell Cardiol. 2004; 36: 691-700.
72. Gbadebo TD, Trimble RW, Khoo MS, et al. Calmodulin inhibitor w-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation. 2002; 105: 770-4.
73. Mazur A, Roden DM, Anderson ME. Systemic administration of calmodulin antagonist w-7 or protein kinase a inhibitor h-8 prevents torsade de pointes in rabbits. Circulation. 1999; 100: 2437-42.
74. Hidaka H, Yamaki T, Asano M, et al. Involvement of calcium in cyclic nucleotide metabolism in human vascular smooth muscle. Blood Vessels. 1978; 15: 55-64.
75. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992; 71: 1231-41.
76. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110: 904-10.
77. Morita N, Lee JH, Xie Y, et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol. 2011; 57: 366-75.
78. Sossalla S, Maurer U, Schotola H, et al. Diastolic dysfunction and arrhythmias caused by overexpression of camkiidelta(c) can be reversed by inhibition of late na(+) current. Basic Res Cardiol. 2011; 106: 263-72.
79. Antoons G, Oros A, Beekman JD, et al. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010; 55: 801-9.
80. Dhalla AK, Wang WQ, Dow J, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009; 297: H1923-9.
81. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non st-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non st-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (merlin-timi 36) randomized controlled trial. Circulation. 2007; 116: 1647-52.
82. Song Y, Shryock JC, Wagner S, et al. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006; 318: 214-22.
83. Undrovinas AI, Belardinelli L, Undrovinas NA, et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006; 17 Suppl 1: S169-77.
84. Wu L, Shryock JC, SongY, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-qt syndrome. J Pharmacol Exp Ther. 2004; 310: 599-605.
85. Fraser H, Belardinelli L, Wang L, et al. Ranolazine decreases diastolic calcium accumulation caused by atx-ii or ischemia in rat hearts. J Mol Cell Cardiol. 2006; 41: 1031-8.
86. Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late ina in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004; 44: 192-9.
87. Sicouri S, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of the highly selective late sodium channel current blocker gs-458967. Heart Rhythm. 2013; 10: 1036-43.
88. Belardinelli L, Liu G, Smith-Maxwell C, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther. 2013; 344: 23-32.
89. Yang ZF, Li CZ, WangW, et al. Electrophysiological mechanisms of sophocarpine as a potential antiarrhythmic agent. Acta Pharmacol Sin. 2011; 32: 311-20.
90. Zhang S, Ma J, Zhang P, Luo A, Ren Z, Kong L. Sophocarpine attenuates the na+-dependent ca2+ overload induced by anemonia sulcata toxin ii-increased late sodium current in rabbit ventricular myocytes. J Cardiovasc Pharmacol. 2012; 60: 357-66.
91. Ke J, Chen F, Zhang C, et al. Effects of calmodulin-dependent protein kinase ii inhibitor, kn-93, on electrophysiological features of rabbit hypertrophic cardiac myocytes. J Huazhong Univ Sci Technol Med Sci. 2012; 32: 485-9.
92. Fukunaga K, Muller D, Miyamoto E. Cam kinase ii in long-term potentiation. Neurochem Int. 1996; 28: 343-58.
93. Ashpole NM, Song W, Brustovetsky T, et al. Calcium/calmodulindependent protein kinase ii (camkii) inhibition induces neurotoxicity via dysregulation of glutamate/calcium signaling and hyperexcitability. J Biol Chem. 2012; 287: 8495-506.